Cargando…
Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
BACKGROUND: Malignant mesothelioma (MM) is a rare disease, linked to asbestos exposure in more than 80% of the cases. Matrix metalloproteinases (MMPs) have been identified as modulators of the tumour microenvironment and carcinogenesis. Polymorphisms of selected MMPs have been studied as potential b...
Autores principales: | Strbac, Danijela, Goricar, Katja, Dolzan, Vita, Kovac, Viljem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043883/ https://www.ncbi.nlm.nih.gov/pubmed/30018519 http://dx.doi.org/10.2478/raon-2018-0005 |
Ejemplares similares
-
Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2017) -
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2019) -
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014) -
Serum Calretinin as a Biomarker in Malignant Mesothelioma
por: Zupanc, Cita, et al.
Publicado: (2021) -
Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma
por: Goričar, Katja, et al.
Publicado: (2017)